<?xml version='1.0' encoding='utf-8'?>
<document id="28513856"><sentence text="The Utility of a Population Approach in Drug-Drug Interaction Assessments: A Simulation Evaluation." /><sentence text="This study aims at evaluating the utility of the population pharmacokinetics approach in therapeutic protein drug-drug-interaction (DDI) assessment" /><sentence text=" Simulations were conducted for 2 representative victim drugs, methotrexate and trastuzumab, using a parallel-group design with and without the interaction drug"><entity charOffset="63-75" id="DDI-PubMed.28513856.s3.e0" text="methotrexate" /><entity charOffset="80-91" id="DDI-PubMed.28513856.s3.e1" text="trastuzumab" /><pair ddi="false" e1="DDI-PubMed.28513856.s3.e0" e2="DDI-PubMed.28513856.s3.e0" /><pair ddi="false" e1="DDI-PubMed.28513856.s3.e0" e2="DDI-PubMed.28513856.s3.e1" /></sentence><sentence text=" The effect of a perpetrator on the exposure of the victim drug is described as the ratio of clearance/apparent clearance of the victim drug given with or without the perpetrator" /><sentence text=" The power of DDI assessment was calculated as the percentage of runs with 90% confidence interval of the estimated DDI effect within 80% to 125% for the scenarios of no DDI, benchmarked with the noncompartmental approach with intensive sampling" /><sentence text=" The impact of the number of subjects, the number of sampling points per subject, sampling time error, and model misspecification on the power of DDI determination were evaluated" /><sentence text=" Results showed that with equal numbers of subjects in each arm, the population pharmacokinetics approach with sparse sampling may need about the same or a higher number of subjects compared to a noncompartmental approach in order to achieve similar power" /><sentence text=" Increasing the number of subjects, even if only in the study drug alone arm, can increase the power" /><sentence text=" Sampling or dosing time error had notable impacts on the power for methotrexate but not for trastuzumab"><entity charOffset="68-80" id="DDI-PubMed.28513856.s9.e0" text="methotrexate" /></sentence><sentence text=" Model misspecification had no notable impacts on the power for trastuzumab" /><sentence text=" Overall, the population pharmacokinetics approach with sparse sampling built in phase 2/3 studies allows appropriate DDI assessment with adequate study design and analysis and can be considered as an alternative to dedicated DDI studies" /><sentence text="" /></document>